Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 160-167 , April 2011

5-Azacytidine in myelodysplastic syndromes: A clinical practice guideline

  • Rena Buckstein

      Affiliations

    • Myelodysplastic Syndromes Program, The Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • Department of Medicine, Faculty of Medicine, University of Toronto, Canada
    • ,
  • Karen Yee

      Affiliations

    • Department of Medicine, Faculty of Medicine, University of Toronto, Canada
    • Princess Margaret Hospital, University Health Network, Toronto, Canada
    • ,
  • Richard A. Wells

      Affiliations

    • Myelodysplastic Syndromes Program, The Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • Department of Medicine, Faculty of Medicine, University of Toronto, Canada
    • J. Douglas Crashley MDS Research Laboratory, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
    • Corresponding Author InformationCorresponding author at: Myelodysplastic Syndromes Program, The Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada. Tel.: +1 416 480 5700; fax: +1 416 480 6002.
    • ,
  • The Canadian Consortium on Evidence-based Care in MDS

Received 16 April 2010 ,Accepted 27 May 2010.

References 

  1. Brunning R, Bennett J, Flandrin G, et al. WHO classification of tumours: pathology and genetics of tumours of haematopoeitic and lymphoid tissues. Lyon: IARC Press; 2001;
  2. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Brit J Haematol. 1982;51:189–199
  3. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica. 1998;83:71–86
  4. Aul C, Gattermann N, Schneider W. Epidemiological and etiological aspects of myelodysplastic syndromes. Leukemia Lymphoma. 1995;16:247–262
  5. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol. 2008;87:691–699
  6. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2004;297–317
  7. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542
  8. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leukemia Res. 2003;27:95–120
  9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009;10:223–232
  10. Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol. 2002;20:2429–2440
  11. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol. 2006;24:3895–3903
  12. Kornblith AB, Herndon JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol. 2002;20:2441–2452
  13. Lyons RM, Cosgriff TM, Modi SS, et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol. 2009;27:1850–1856
  14. Raza A, Mehdi M, Mumtaz M, Ali F, Lascher S, Galili N. Combination of 5-azacytidine and thalidomide for the treatment of myelodysplastic syndromes and acute myeloid leukemia. Cancer. 2008;113:1596–1604
  15. Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood. 2007;110:2302–2308
  16. Nand S, Godwin J, Smith S, et al. Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial. Leukemia Lymphoma. 2008;49:2141–2147
  17. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol. 2005;45:597–602
  18. Silverman LR, Holland JF, Weinberg RS, et al. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia. 1993;7(Suppl. 1):21–29
  19. List A, Fenaux G, Mufti J, et al. Effect on overall survival in higher-risk myelodysplastic syndromes (MDS) without complete remission. In: J Clin Oncol; 2008.
  20. Mufti G, Fenaux G, Hellstrom-Lindberg E, et al. Treatment of high-risk MDS patients (pts) with −7/del (7q) with azacitidine (AZA) versus conventional care regimens (CCR): effects on overall survival. In: J Clin Oncol: ASCO; 2008. p. 26 [abstract 7033].
  21. Seymour J, Fenaux P, Silverman L, et al. Effects of azacitidine (AZA) vs conventional care regimens (CCR) in elderly (⩾75 yrs) patients (Pts) with myelodysplastic syndromes (MDS) from the AZA-001 survival trial. In: ASH: Blood; 2008 [abstract 3629].
  22. Fenaux G, Mufti G, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients (Pts) with WHO-defined acute myeloid leukemia (AML) compared with conventional care regimens (CCR). In: ASH, San Francisco: Blood; 2008 [abstract 3636].
  23. Silverman L, Fenaux G, Mufti G, et al. The effects of continued azacitidine (AZA) treatment cycles on response in higher-risk patients (Pts) with myelodysplastic syndromes (MDS). In: ASH, San Francisco: Blood; 2008 [abstract 227].
  24. Santini V, Fenaux G, Mufti G, et al. Management and supportive care measures of adverse events in higher risk MDS patients treated with azacitidine (AZA). In: Blood; 2008 [Abstract 1653].
  25. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood. 2000;96:3671–3674
  26. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108:419–425
  27. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088
  28. Cheson BD. Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes. Leukemia Res. 1998;22(Suppl. 1):S17–S21
  29. Cheson BD, Simon R. Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years’ experience. Semin Oncol. 1987;14:126–133
  30. Hellstrom-Lindberg E, Robert KH, Gahrton G, et al. A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia. Brit J Haematol. 1992;81:503–511
  31. Gajewski JL, Ho WG, Nimer SD, et al. Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome. J Clin Oncol. 1989;7:1637–1645
  32. Verbeek W, Wormann B, Koch P, et al. S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes. Ann Hematol. 1997;74:205–208
  33. Estey EH, Thall PF, Cortes JE, et al. Comparison of idarubicin+ara-C-, fludarabine+ara-C-, and topotecan+ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts. Blood. 2001;98:3575–3583
  34. de Witte T, Suciu S, Verhoef G, et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood. 2001;98:2326–2331
  35. Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090–1098
  36. Knipp S, Hildebrand B, Kundgen A, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007;110:345–352
  37. Hofmann WK, Heil G, Zander C, et al. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia. Ann Hematol. 2004;83:498–503
  38. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004;104:579–585
  39. Barrett AJ, Savani BN. Allogeneic stem cell transplantation for myelodysplastic syndrome. Semin Hematol. 2008;45:49–59
  40. Burnett A, Milligan D, Prentic A, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–1124
  41. Brechignac S, Hellstrom-Lindberg E, Bowen DT, DeWitt TM, Cazzola M, Fenaux P. Quality of life and economic impact of red blood cell (RBC) transfusions on patients with myelodysplastic syndromes (MDS) In: ASH: Blood; 2004. p. 263b.

PII: S0305-7372(10)00105-2

doi: 10.1016/j.ctrv.2010.05.006

Cancer Treatment Reviews
Volume 37, Issue 2 , Pages 160-167 , April 2011

Article Tools